Evidence map›Paper›PMID 36578937›Full record

ArticleFrontiers in oncology2022

Case report: Complete pathologic response with first-line immunotherapy combination in a young adult with massive liver dissemination of mismatch repair-deficient metastatic colorectal cancer: Immunological and molecular profiling.

Francesca Bergamo, Silvia Dalla Santa, Fotios Loupakis, Krisida Cerma, Anna Tosi, Caterina De Grandis, Anna Dalla Pietà, Enrico Gringeri, Valentina Angerilli, Gaetano Ramondo and 9 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Francesca BergamoOncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Silvia Dalla SantaDepartment of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
Fotios LoupakisOncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Krisida CermaOncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Anna TosiImmunology and Molecular Oncology Diagnostics Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Caterina De GrandisOncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Anna Dalla PietàDepartment of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
Enrico GringeriHepatobiliary Surgery and Liver Transplantation Unit, Department of Surgery, Oncology and Gastroenterology, Padua University Hospital, Padua, Italy.
Valentina AngerilliSurgical Pathology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Gaetano RamondoRadiology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Alessandro RagoRadiology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Fabiola CecchiNantOmics, Rockville, MD, United States.
Stephen BenzNantOmics, Rockville, MD, United States.
Umberto CilloHepatobiliary Surgery and Liver Transplantation Unit, Department of Surgery, Oncology and Gastroenterology, Padua University Hospital, Padua, Italy.
Angelo Paolo Dei TosSurgical Pathology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Vittorina ZagonelOncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Matteo FassanSurgical Pathology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Antonio RosatoDepartment of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
Sara LonardiOncology Unit 3, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Istituto Oncologico Veneto · ITUniversity of Padua · ITIstituti di Ricovero e Cura a Carattere Scientifico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current level of evidence for immunotherapy in previously untreated microsatellite unstable metastatic colorectal cancer is based on recent pieces of evidence of few studies that demonstrated durable response and clinical benefit, in terms of objective response rate, disease control rate, and progression-free survival in this subgroup of patients. On the basis of combinatorial immunotherapy with nivolumab plus ipilimumab, we report the exceptional case of a complete pathological response in a 21-year-old woman presenting a clinically aggressive stage IV colorectal cancer with massive nodal and liver involvement. Extensive molecular analyses based on whole genome next-generation DNA sequencing, RNA sequencing, fluorescent multiplex immunohistochemistry, and flow cytometry provided a detailed description of tumoral and immunological characteristics of this noteworthy clinical case.

Indexed as

colorectal cancercomplete pathological responseipilimumabMSI-Hnivolumab

Identifiers

PMID36578937
PMCPMC9791944
OpenAlexW4311858110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.